GRAIL Inc Revenue Breakdown – LSX:A40F8M
GRAIL Inc (LSX:A40F8M) generated 125.31 million EUR in revenue last year. The majority of this revenue, 118.01 million EUR, came from its top-performing "Screening" segment, an increase from 104.93 million EUR in the previous year. The United States was the largest geographical contributor, accounting for 116.72 million EUR in revenue.
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026
Faruqi & Faruqi, LLP is investigating potential securities claims against Grail, Inc. (NASDAQ: GRAL) and reminds investors that the deadline to seek the role of lead plaintiff in a federal securities class action lawsuit is August 4, 2026. The lawsuit alleges that Grail made false and misleading statements regarding the success likelihood of its NHS-Galleri trial, leading to a significant stock price drop after the company announced its primary endpoint was not met. Investors who purchased GRAL stock between May 13, 2024, and February 19, 2026, and suffered losses are encouraged to contact the firm.
Portnoy Law Firm Announces Class Action on Behalf of Grail, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in Grail, Inc. (NASDAQ: GRAL) who purchased securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that Grail made misleading statements and concealed material adverse facts regarding the true state of its NHS-Galleri trial, specifically concerning the sufficiency of the trial period to demonstrate a reduction in Stage III-IV cancers. Investors are encouraged to contact the firm to discuss their legal rights.
GRAL DEADLINE TODAY: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL), urging investors with substantial losses to join before the August 4, 2026, lead plaintiff deadline. The lawsuit alleges that GRAIL and its executives misled investors about the NHS-Galleri cancer screening trial's design and efficacy, particularly concerning the sufficiency of its three-year follow-up period. GRAIL's stock plummeted by 50.55% on February 19, 2026, after the company disclosed that the trial failed to meet its primary endpoint and admitted to a flawed timeline, leading to over $2.2 billion in market cap loss.
$GRAL Securities: Suffer Losses on Your GRAIL, Inc.
Bleichmar Fonti & Auld LLP has filed a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) and its executives for securities fraud. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial, causing a 50% stock drop after the trial failed to meet its primary endpoint. Investors who suffered losses are encouraged to contact BFA Law before the August 4, 2026, lead plaintiff deadline.
GRAIL to Present at the Canaccord Genuity 46th Annual Growth Conference
GRAIL, Inc., a healthcare company focused on early cancer detection, announced it will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11 at 10:00 a.m. ET. The company aims to alleviate the global burden of cancer by using advanced sequencing and machine learning to detect multiple cancer types in earlier stages. A webcast of the presentation will be available on GRAIL's investor relations website.
GRAIL to Present at the Canaccord Genuity 46th Annual Growth Conference
GRAIL (Nasdaq: GRAL) announced that its management will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, at 10:00 a.m. ET. Live and replay webcasts of the presentation will be available through GRAIL's investor relations website, with the replay archived for at least 30 days. This event provides investors with an opportunity to learn more about GRAIL's mission to detect cancer early.
GRAL Deadline: Rosen Law Firm Urges GRAIL, Inc. (NASDAQ: GRAL) Stockholders to Contact the Firm for Information About Their Rights
Rosen Law Firm is notifying stockholders of GRAIL, Inc. (NASDAQ: GRAL) about a class action lawsuit for alleged misleading statements made between May 13, 2025, and February 19, 2026. The lawsuit claims GRAIL concealed material adverse facts regarding its NHS-Galleri trial's sufficiency to demonstrate a reduction in Stage III-IV cancers. Shareholders have until August 4, 2026, to file as lead plaintiff.
Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) alleging violations of federal securities laws. The lawsuit claims that Grail and its officers made false and misleading statements regarding the likelihood of achieving the primary endpoint in Grail’s NHS-Galleri trial, thereby harming investors. Investors who purchased Grail securities between May 13, 2025, and February 19, 2026, are encouraged to join the class action, with a lead plaintiff deadline of August 4, 2026.
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 4, 2026 in Grail, Inc. Lawsuit - GRAL
SueWallSt is reminding shareholders of Grail, Inc. (NASDAQ: GRAL) about the lead plaintiff deadline of August 4, 2026, in a securities class action lawsuit. The lawsuit alleges that Grail's management made misleading representations about the NHS-Galleri trial, leading to a significant stock price drop after the trial's primary endpoint was not met. Investors who purchased GRAL securities between May 13, 2025, and February 19, 2026, and suffered losses, may be eligible for compensation and are encouraged to contact SueWallSt for a no-cost case evaluation.
Levi & Korsinsky Reminds Grail, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 4, 2026 - GRAL
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Grail, Inc. (NASDAQ: GRAL), reminding investors who purchased stock between May 13, 2025, and February 19, 2026, of the August 4, 2026 lead plaintiff deadline. The lawsuit alleges that Grail's leadership withheld crucial internal data suggesting the NHS-Galleri trial's three-year design was insufficient to achieve its primary endpoint, leading to a significant stock price drop when the trial failed. Investors who suffered losses are encouraged to contact the firm to recover damages.
GRAIL to Announce Second Quarter 2026 Financial Results
GRAIL, Inc. (Nasdaq: GRAL) announced it will release its second-quarter 2026 financial results after market close on Wednesday, August 5, 2026. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and business progress. Interested parties can find a link to the live webcast and recorded replay on the investor relations section of GRAIL's website.
Bragar Eagel & Squire, P.C. Reminds GRAIL, Inc. Investors
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against GRAIL, Inc. on behalf of investors who purchased common stock between May 13, 2025, and February 19, 2026. The lawsuit alleges that GRAIL made false and misleading statements regarding the NHS Galleri trial, specifically concerning its sufficiency to demonstrate a reduction in Stage III-IV cancers and the company's refusal to provide detailed trial results. Investors have until August 4, 2026, to apply for lead plaintiff status.
Bragar Eagel & Squire, P.C. Reminds GRAIL, Inc. Investors They Have Until August 4th to Contact the Firm Seeking Lead Plaintiff Rol
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) for allegedly making false and misleading statements regarding its NHS Galleri trial. Investors who purchased GRAIL common stock between May 13, 2025, and February 19, 2026, and suffered losses are encouraged to contact the firm by August 4, 2026, to discuss potentially becoming lead plaintiff. The lawsuit claims GRAIL concealed issues with the trial's ability to demonstrate a reduction in Stage III-IV cancers, leading to a significant stock price drop after negative trial results were revealed on February 19, 2026.
GRAIL webcast on Aug. 5 results open to all interested parties
GRAIL (Nasdaq: GRAL) will announce its second quarter 2026 financial results after market close on Wednesday, August 5, 2026. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and business progress. The live webcast and recorded replay will be accessible via the investor relations section of GRAIL's website, and interested participants are encouraged to register in advance.
Levi & Korsinsky Reminds Grail, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 4, 2026 - GRAL
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Grail, Inc. (NASDAQ: GRAL), reminding investors who purchased stock between May 13, 2025, and February 19, 2026, of the pending class action. The lawsuit alleges that Grail's leadership withheld crucial information about the NHS-Galleri trial's insufficient timeline, despite internal data suggesting the trial would fail its primary endpoint. GRAL shares experienced a significant decline of 50.55%, or $51.32 per share, after the trial's failure was disclosed, and investors have until August 4, 2026, to submit lead plaintiff applications.
GRAIL, INC. INVESTORS WITH LOSSES HAVE UNTIL AUGUST 4, 2026
Bernstein Liebhard LLP reminds GRAIL, Inc. (NASDAQ: GRAL) investors that they have until August 4, 2026, to join a securities fraud class action lawsuit. The lawsuit alleges that GRAIL made materially false and misleading statements between May 13, 2025, and February 19, 2026, leading to artificially inflated stock prices and investor losses. Investors who purchased shares during this period and suffered losses are encouraged to contact the firm.
GRAL Court Deadline: GRAIL, Inc. Investor Deadline in Securities Fraud Class Action is August 4 – Contact BFA Law if You Lost Money
Bleichmar Fonti & Auld LLP has announced a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) and its executives. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial, which caused a 50.55% stock drop on February 20, 2026, after the trial failed to meet its primary endpoint. Investors who lost money are encouraged to contact BFA Law by the lead plaintiff deadline of August 4, 2026.
BlackRock (GRAL holder) discloses 7.9% GRAIL, Inc. stake in 13G/A
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 7.9% passive ownership stake in GRAIL, Inc. (GRAL). This ownership amounts to 3,376,085 shares of GRAIL common stock, with BlackRock holding sole voting power over 3,312,474 shares and sole dispositive power over all 3,376,085 shares. The filing indicates that no single client of BlackRock exceeds five percent of GRAIL's outstanding common shares.
GRAL 1-WEEK DEADLINE ALERT: GRAIL, Inc. (NASDAQ: GRAL)
Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL), urging investors with substantial losses to join before the August 4, 2026, lead plaintiff deadline. The lawsuit alleges that GRAIL and its executives misled investors about the design and efficacy of its NHS-Galleri cancer screening trial, failing to disclose limitations and resulting in a significant stock price collapse. The firm is investigating when management knew about the trial's flawed timeline.
Portnoy Law Firm Announces Class Action on Behalf of Grail, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit against Grail, Inc. (NASDAQ: GRAL) on behalf of investors who purchased securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that Grail disseminated materially false and misleading statements regarding its NHS-Galleri trial, concealing that the trial design was insufficient to demonstrate a reduction in Stage III-IV cancers within the specified follow-up period. Investors have until August 4, 2026, to file a lead plaintiff motion.
Portnoy Law Firm Announces Class Action on Behalf of Grail, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit against Grail, Inc. on behalf of investors who purchased securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that Grail made false and misleading statements about the NHS-Galleri trial results, concealing that the trial period was insufficient to demonstrate a reduction in Stage III-IV cancers. Investors have until August 4, 2026, to file a lead plaintiff motion.
Lost Money on GRAIL, Inc. (GRAL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
The Gross Law Firm has issued a notice to shareholders of GRAIL, Inc. (NASDAQ: GRAL) who purchased shares between May 13, 2025, and February 19, 2026. The firm encourages these shareholders to join a class action lawsuit seeking recovery, stating that the company allegedly provided false and misleading statements regarding its NHS-Galleri trial's potential to reduce Stage III-IV cancers. Following the announcement that the trial's primary endpoint was not met, GRAIL's stock price dramatically declined by over 50% in one day.
Pomerantz LLP Shares Class Action Details With Investors in GRAIL, Inc. – GRAL
Pomerantz LLP has announced a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) following a significant drop in its stock price. The lawsuit stems from Grail's announcement on February 19, 2026, that its NHS-Galleri Trial did not meet its primary endpoint, leading to a more than 50% decline in stock value. Investors who purchased Grail securities during the Class Period have until August 4, 2026, to seek appointment as Lead Plaintiff.
GRAL DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important August 4 Deadline in Securities Class Action – GRAL
Rosen Law Firm is reminding investors who purchased GRAIL, Inc. (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, about the August 4, 2026, lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that GRAIL made materially false and misleading statements and/or concealed material adverse facts regarding its NHS-Galleri trial, specifically concerning its sufficiency to demonstrate a reduction in Stage III-IV cancers. Investors are encouraged to contact the Rosen Law Firm to join the class action and potentially recover damages.
$GRAL Lawsuit Notice: BFA Law Reminds GRAIL, Inc. Investors
BFA Law has filed a securities fraud class action lawsuit against GRAIL, Inc. following a 50% stock drop. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial by making positive statements about the trial's design and results, despite the three-year timeframe being insufficient to demonstrate the primary endpoint. Investors have until August 4, 2026, to seek lead plaintiff status in the case.
AUGUST 4, 2026 GRAL DEADLINE: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces a shareholder class action lawsuit against GRAIL, Inc. and its executives for alleged Securities Exchange Act violations. The lawsuit claims that Grail made false and misleading statements regarding its NHS-Galleri trial's primary endpoint, which was not achieved, leading to a significant stock price drop. Investors who suffered substantial losses between
GRAIL, Inc. ($GRAL) Investors Notified of August 4 Court Deadline in Securities Fraud Lawsuit Over Trial Results Allegations
A class action lawsuit has been filed against GRAIL, Inc. (NASDAQ: GRAL) and its executives for securities fraud, stemming from a significant stock drop after the NHS-Galleri cancer trial failed to meet its primary endpoint. Investors have until August 4, 2026, to seek lead plaintiff status in the case, which alleges the company made misleading statements about the trial's design and results. The lawsuit claims GRAIL's stock fell over 50% following the announcement that the trial did not show a statistically significant reduction in late-stage cancers.
GRAL 10-DAY DEADLINE ALERT: GRAIL, Inc. (NASDAQ: GRAL)
Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL), urging investors with substantial losses to come forward by the August 4, 2026, lead plaintiff deadline. The lawsuit alleges that GRAIL misled investors about the clinical design and efficacy of its NHS-Galleri cancer screening trial, failing to disclose limitations which led to a 50.55% stock price collapse on February 19, 2026, after the trial failed to meet its primary endpoint. Hagens Berman is investigating whether management knew earlier about the insufficient follow-up period.
Securities Fraud Class Action Filed Against GRAIL, Inc. (GRAL) - Levi & Korsinsky Reminds Investors of August 4, 2026
Levi & Korsinsky, LLP has filed a securities class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) on behalf of investors who purchased securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that GRAIL made misleading statements regarding its NHS-Galleri trial, ultimately revealing that the primary endpoint of reducing Stage III-IV cancers was not met, leading to a significant stock price drop. Investors who suffered losses are encouraged to contact the firm to explore potential recovery options.
GRAIL Inc Revenue Breakdown – HAN:NL0
GRAIL Inc (NL0) generated 125.31 million EUR in revenue last year. The majority of this revenue, 118.01 million EUR, came from its top segment, Screening, showing an increase from the previous year's 104.93 million EUR. The United States was the largest contributor to the company's revenue, accounting for 116.72 million EUR.
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead Grail Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against GRAIL, Inc. (GRAL) for investors who purchased stock between May 13, 2025, and February 19, 2026, and suffered significant losses. The lawsuit alleges that Grail made misleading statements about the probability of success for its NHS-Galleri trial, specifically regarding a statistically significant reduction in late-stage cancers, which ultimately was not observed. Investors have until August 4, 2026, to seek appointment as lead plaintiff in the case.
Priority Health Launches 2 Cancer Support Solutions with Color Health, Grail
Priority Health has partnered with Color Health and Grail to introduce two new cancer support solutions for self-funded employers. These solutions, available from January 1, 2027, will offer virtual cancer navigation, support, and multi-cancer early detection to Priority Health's 1.4 million members. The aim is to proactively address cancer earlier, provide personalized support, and potentially reduce healthcare costs associated with late-stage diagnoses.
GRAL Shareholder Alert: GRAIL, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm
The Gross Law Firm has issued a shareholder alert for investors of GRAIL, Inc. (GRAL), announcing a securities class action lawsuit. Investors who purchased GRAL shares between May 13, 2020, and February 19, 2026, are encouraged to contact the firm regarding potential lead plaintiff appointment. The lawsuit alleges that GRAIL defendants made misleading statements and concealed adverse facts about the company's NHS-Galleri trial results, leading to a significant stock price drop.
HAGENS BERMAN, SOBOL SHAPIRO LLP ALERT: GRAIL, Inc. (NASDAQ: GRAL) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 4, 2026 Lead Plaintiff Deadline
Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) following a significant stock price drop. The lawsuit alleges that GRAIL and its executives misled investors about the clinical design and efficacy of its NHS-Galleri cancer screening trial, specifically regarding a three-year follow-up period that proved insufficient. Investors who purchased GRAL stock between May 13, 2025, and February 19, 2026, and incurred substantial losses, have until August 4, 2026, to seek lead plaintiff status.
$GRAL Fraud Notification: GRAIL, Inc. Sued for Fraud Over Misrepresentations about its Trial Results – Investors Notified to Contact BFA Law
A securities fraud class action lawsuit has been filed against GRAIL, Inc. (NASDAQ:GRAL) due to a 50% stock dive following allegations that the company misrepresented results from its NHS-Galleri cancer trial. The lawsuit claims GRAIL misled investors regarding the trial's effectiveness and its ability to achieve its primary endpoint of reducing late-stage cancers within the stated three-year timeframe. Investors are encouraged to contact BFA Law to discuss their legal options, with a lead plaintiff deadline of August 4, 2026.
How Grail Inc Com (GRAL) Affects Rotational Strategy Timing
The article analyzes Grail Inc Com (GRAL) through a quantitative research lens, highlighting weak near-term sentiment that could precede shifts in its mid and long-term outlook. It identifies resistance levels and an exceptional short setup with significant downside potential against low risk. Several institutional trading strategies, including position, momentum, and risk hedging, are detailed along with multi-timeframe signal analysis to guide investors.
GRAL INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026
Faruqi & Faruqi, LLP reminds investors of a securities class action lawsuit against Grail, Inc. (GRAL) with a lead plaintiff deadline of August 4, 2026. The lawsuit alleges that Grail made misleading statements regarding the success of its NHS-Galleri cancer detection trial, which resulted in a significant stock price drop. Investors who purchased GRAL securities between May 13, 2025, and February 19, 2026, and suffered losses are encouraged to contact the law firm.
Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) and its officers, alleging violations of federal securities laws. The lawsuit seeks damages for investors who purchased Grail securities between May 13, 2025, and February 19, 2026, claiming that defendants made false and misleading statements regarding the likelihood of success in Grail's NHS-Galleri trial. Investors are encouraged to join the case, with an August 4, 2026, deadline to request appointment as lead plaintiff.
Grail, Inc. (GRAL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
The Law Offices of Frank R. Cruz have announced a securities fraud class action lawsuit against Grail, Inc. (GRAL), inviting investors who suffered losses to become lead plaintiffs. The lawsuit alleges that Grail's management made misleading statements about the company's business and prospects, particularly regarding the sufficiency of a three-year trial to achieve a primary endpoint, leading to significant investor losses. Interested shareholders are encouraged to contact the firm before the August 4, 2026, lead plaintiff deadline.
Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) alleging violations of federal securities laws. The lawsuit claims that Grail and its officers made false and misleading statements regarding the likelihood of achieving the primary endpoint in the NHS-Galleri trial, thereby harming investors who purchased securities between May 13, 2025, and February 19, 2026. Investors are encouraged to join the lawsuit, with a lead plaintiff deadline of August 4, 2026.
Lost Money on Grail, Inc. (GRAL)? Join Class Action Suit Seeking Recovery - Contact SueWallSt
SueWallSt is announcing a securities class action lawsuit against Grail, Inc. (GRAL) on behalf of shareholders who experienced significant losses after the company's NHS-Galleri trial failed to meet its primary endpoint. Investors are encouraged to seek lead plaintiff status by August 4, 2026, though class members can still participate in a settlement even if they miss this deadline. The lawsuit alleges that Grail made misleading statements about the trial's progress and expected outcomes, leading to a 50.55% stock drop when the failure was disclosed.
Lost Money on Grail, Inc. (GRAL)? Join Class Action Suit Seeking Recovery - Contact SueWallSt
SueWallSt.com is providing information regarding a pending securities class action suit against Grail, Inc. (NASDAQ: GRAL) for investors who purchased shares between May 13, 2025, and February 19, 2026. The lawsuit stems from a 50.55% stock price collapse after the company's NHS-Galleri trial failed to meet its primary endpoint, contradicting earlier positive characterizations by management. Shareholders have until August 4, 2026, to seek lead plaintiff appointment to potentially recover losses.
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against GRAIL, Inc. (GRAL)
Bernstein Liebhard LLP has announced a securities class action lawsuit filed against GRAIL, Inc. on behalf of investors who purchased common stock between May 13, 2025, and February 19, 2026. The lawsuit alleges that GRAIL made false and misleading statements, leading to artificially inflated stock prices and significant losses for investors. Shareholders are encouraged to join the lawsuit, with a lead plaintiff deadline of August 4, 2026.
GRAIL, INC. INVESTORS WITH LOSSES HAVE UNTIL AUGUST 4, 2026
Bernstein Liebhard LLP reminds investors of GRAIL, Inc. (NASDAQ: GRAL) that they have until August 4, 2026, to join a securities fraud class action lawsuit. The lawsuit alleges that GRAIL made false and misleading statements between May 13, 2025, and February 19, 2026, causing investors to suffer losses. Investors who purchased shares during this period and wish to serve as lead plaintiff must file papers by the deadline.
GRAL Deadline Alert: Levi & Korsinsky Reminds Grail, Inc. (GRAL) Investors of Securities Class Action Deadline on August 4, 2026
Levi & Korsinsky reminds investors of Grail, Inc. (NASDAQ: GRAL) that the deadline to apply for lead plaintiff in a securities class action lawsuit is August 4, 2026. This lawsuit follows a significant stock drop after Grail's NHS-Galleri trial failed its primary endpoint, resulting in losses of over 50% for investors who purchased securities between May 13, 2025, and February 19, 2026. The firm encourages affected shareholders to contact them to evaluate their eligibility to recover losses or serve as a lead plaintiff.
GRAL Deadline Alert: Levi & Korsinsky Reminds Grail, Inc. (GRAL) Investors of Securities Class Action Deadline on August 4, 2026
Levi & Korsinsky, LLP is reminding investors of Grail, Inc. (GRAL) about the August 4, 2026 deadline to seek lead plaintiff appointment in a securities class action lawsuit. This alert follows a significant stock drop of over 50% after Grail's NHS-Galleri trial failed to meet its primary endpoint on February 19, 2026. Investors who purchased GRAL securities between May 13, 2025, and February 19, 2026, and suffered losses are encouraged to contact the firm to evaluate their options.
INVESTOR NOTICE: GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action- Hagens Berman
Hagens Berman is investigating GRAIL, Inc. (NASDAQ: GRAL) for alleged securities law violations in connection with its NHS-Galleri cancer screening trial. The lawsuit claims GRAIL misled investors about the trial's design and efficacy, particularly regarding the adequacy of the three-year follow-up period, leading to a significant stock drop after the trial failed its primary endpoint. Investors who suffered substantial losses are encouraged to come forward and have until August 4, 2026, to seek lead plaintiff status.
Portnoy Law Firm Announces Class Action on Behalf of Grail, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit on behalf of investors who purchased Grail, Inc. (NASDAQ: GRAL) securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that Grail disseminated false and misleading statements about the NHS-Galleri trial, concealing that the trial period was insufficient to achieve its primary endpoint of reducing Stage III-IV cancers. Investors have until August 4, 2026, to file a lead plaintiff motion.
GRAL Deadline Alert: The Gross Law Firm Reminds GRAIL, Inc. (GRAL) Investors of Securities Class Action Deadline on August 4, 2026
The Gross Law Firm has issued an alert reminding investors of GRAIL, Inc. (GRAL) about a securities class action lawsuit deadline on August 4, 2026. The lawsuit alleges that GRAIL made false and misleading statements regarding the NHS-Galleri trial, specifically that the trial period was insufficient to achieve its primary endpoint, leading to a significant stock price decline on February 19, 2026. Shareholders who purchased GRAL shares between May 13, 2025, and February 19, 2026, are encouraged to contact the firm regarding potential lead plaintiff appointment.
